Fabry disease treatment market value to reach $1.25 bn by 2024

The company's latest report states that this value increase, which will occur across the seven major markets, represents a moderate CAGR of 6.3%

lysosomal-storage-disease

(Photo Courtesy: www.thelancet.com)

The global treatment market for Fabry disease will expand in value from $683 million in 2014 to approximately $1.25 billion by 2024, driven primarily by rising physician awareness of the condition and consequently higher diagnosis rates, according to research and consulting firm GlobalData.

The company's latest report states that this value increase, which will occur across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, UK, and Japan, represents a moderate Compound Annual Growth Rate (CAGR) of 6.3%.

Dr Valentina Gburcik, GlobalData's director of cardiovascular and metabolic disorders, says that alongside increasing diagnosed cases, the market entry of the first pharmacological chaperone for the treatment of Fabry disease, namely Amicus' migalastat, will also boost growth.

She comments: "Migalastat is anticipated to launch in the US and five European countries (5EU) in 2017, before entering the Japanese market in 2020.

"The patient share for migalastat is not only expected to be captured from existing patients receiving enzyme replacement therapy (ERT), but also treatment-naïve patients that have not previously been considered suitable for ERT, including children, and adults with late-onset, less severe cases of Fabry disease."

 

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X